ACES Stock Overview
A biotech company, focuses on orphan oncology treatments in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Ascelia Pharma AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 20.55 |
| 52 Week High | SEK 20.55 |
| 52 Week Low | SEK 20.45 |
| Beta | 0.74 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 9.60% |
Recent News & Updates
Recent updates
Shareholder Returns
| ACES | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0% | -4.2% | -2.6% |
| 1Y | n/a | -24.5% | 2.4% |
Return vs Industry: Insufficient data to determine how ACES performed against the UK Biotechs industry.
Return vs Market: Insufficient data to determine how ACES performed against the UK Market.
Price Volatility
| ACES volatility | |
|---|---|
| ACES Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.7% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: ACES has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine ACES's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 21 | Magnus Corfitzen | www.ascelia.com |
Ascelia Pharma AB (publ), a biotech company, operates as an oncology-focused orphan drug development company in Sweden. It is developing Mangoral, a novel non-gadolinium contrast agent, which is in Phase 3 for use in MRI-scans of the liver; and Oncoral, a novel oral chemotherapy tablet, which is in Phase 2 for the treatment of gastric cancer. It has a clinical collaboration agreement with Taiho Oncology, Inc. for the development of Oncoral in combination with LONSURF.
Ascelia Pharma AB (publ) Fundamentals Summary
| ACES fundamental statistics | |
|---|---|
| Market cap | SEK 672.69m |
| Earnings (TTM) | -SEK 115.48m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-5.8x
P/E RatioIs ACES overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ACES income statement (TTM) | |
|---|---|
| Revenue | SEK 0 |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 0 |
| Other Expenses | SEK 115.48m |
| Earnings | -SEK 115.48m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
Nov 04, 2022
| Earnings per share (EPS) | -3.43 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did ACES perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/08/31 19:32 |
| End of Day Share Price | 2022/06/03 00:00 |
| Earnings | 2022/06/30 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Ascelia Pharma AB (publ) is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Lars Hevreng | Danske Bank |
| Ludvig Svensson | Penser Access |
| Johan Unnerus | Redeye |